Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 3/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894312 | 1.00 | NOS3 (0.49) | NOS3NOS2AURKANR3C2ALDH1A1 | |
| SCHEMBL17396703 | 0.85 | AGBL2 (0.47) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL29755981 | 0.85 | AGBL2 (0.47) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL17653893 | 0.83 | AGBL2 (0.46) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| Lithium Ion SCHEMBL17396698 | 0.83 | NOS3 (0.44) | NOS3NOS2NR3C2ALDH1A1GAA | |
| SCHEMBL17396700 | 0.83 | AGBL2 (0.46) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL17396822 | 0.82 | NR3C2 (0.34) | NOS3NOS2AURKANR3C2ICMT | |
| SCHEMBL15505079 | 0.80 | ALDH1A1 (0.48) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL17396756 | 0.78 | AGBL2 (0.46) | NOS3NOS2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL17396881 | 0.78 | CYP1A2 (0.42) | ALDH1A1GAAKMT2AGLSMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| WO-2022222911-A1 | PYRIMIDONE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-10-27 | — | — | WO | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| CN-107074805-B | GLS1 inhibitors for the treatment of disease | 德州大学系统董事会 | 2021-02-26 | — | — | CN | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| EP-3164394-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | Board of Regents, The University of Texas System (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NOS3 1868/4885NOS2 1711/4885AURKA 3758/4885 |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NOS3 1868/4885NOS2 1711/4885AURKA 3758/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NOS3 1868/4885NOS2 1711/4885AURKA 3758/4885 |
| US-11370786-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLB1 | NOS3 2395/4885NOS2 2366/4885AURKA 3991/4885 |
| US-11958849-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | NOS3 1868/4885NOS2 1711/4885AURKA 3758/4885 |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NOS3 1868/4885NOS2 1711/4885AURKA 3758/4885 |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | NOS3 251/4885NOS2 138/4885AURKA 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.